How a “cool” trial in rare cancers was born

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

About a year ago, Sandip Patel, a young doctor who had just joined the faculty at University of California San Diego Moores Cancer Center, stopped by to see his mentor, Razelle Kurzrock, chair of the SWOG Early Therapeutics and Rare Cancers Committee.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

With the recent FDA approval of daratumumab for high-risk smoldering multiple myeloma, the moment is ripe to revisit the evolution of our understanding of smoldering multiple myeloma. This development not only underscores the growing recognition of early intervention but also invites a broader reflection on the biological insights and therapeutic strategies that have shaped—and continue to shape—this transitional disease state.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login